Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 39 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Bafaloukos, Dimitrios [Clear All Filters]
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer..
Clin Colorectal Cancer. 17(4), e631-e637.
(2018). Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab..
Clin Colorectal Cancer. 18(4), e370-e384.
(2019). Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes..
BMC Cancer. 13, 49.
(2013). Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes..
PLoS One. 9(3), e91407.
(2014). Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel..
PLoS One. 7(6), e37946.
(2012).
(2014). EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab..
J Cancer Res Clin Oncol. 140(5), 737-48.
(2014). Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab..
Cancer Genomics Proteomics. 15(6), 461-471.
(2018). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015). Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study..
PLoS One. 13(12), e0207707.
(2018). Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study..
Oncol Rep. 27(1), 216-24.
(2012). The fate of BRCA1-related germline mutations in triple-negative breast tumors..
Am J Cancer Res. 7(1), 98-114.
(2017). Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial..
Breast Cancer Res Treat. 116(1), 131-43.
(2009). Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study..
Histol Histopathol. 30(9), 1129-41.
(2015). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012). Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial..
PLoS One. 8(7), e69256.
(2013). Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia..
Mol Clin Oncol. 4(2), 211-220.
(2016). MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer..
J Transl Med. 14(1), 136.
(2016). A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon..
PLoS One. 9(1), e86375.
(2014). Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation..
Anticancer Res. 31(9), 3007-18.
(2011). Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group..
Clin Breast Cancer. 10(3), 230-7.
(2010). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015). Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020).
(2012).
(2012).